Peptide name : CIGB-552

Source/Organism : Synthetic

Linear/Cyclic : Linear

Chirality : Mix

Peptide length: 20

C-terminal modification: Linear

N-terminal modification : Free

Non-natural peptide information:

Assay type : Sulforhodamine B assay

Assay time : 48-h

Activity : IC50 = 287.9 μM

Cell line : NCI-H-460

Cancer type : Lung Cancer

Other activity : Antitumor

Amino acid composition bar chart :

Molecular mass : 2647.1773 Dalton

Aliphatic index : 0.245

Instability index : 23.56

Hydrophobicity (GRAVY) : -1.315

Isoelectric point : 11.763

Charge (pH 7) : 7.8413

Aromaticity : 25

Molar extinction coefficient (cysteine, cystine): (0, 0)

Hydrophobic/hydrophilic ratio : 0.6364

hydrophobic moment : 0.3757

Missing amino acid : C,D,E,L,M,N,P,Q,S,V

Most occurring amino acid : K

Most occurring amino acid frequency : 5

Least occurring amino acid : H

Least occurring amino acid frequency : 1

Secondary structure fraction (Helix, Turn, Sheet): (35, 10, 40)

SMILES Notation: CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)[C@@H](C)O

1 : Gomez Rodriguez Y, et al. Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models. Mol Biol Rep. 2022; 49:3197-3212. doi: 10.1007/s11033-022-07152-3

Paper title : Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models.

Doi : https://doi.org/10.1007/s11033-022-07152-3

Abstract : BACKGROUND: The antitumor peptide CIGB-552 is a new targeted anticancer therapy which molecular mechanism is associated with the inhibition of the transcription factor NF-kB, mediated by COMMD1 protein stabilization. In this study, we examined the antiproliferative capacity of CIGB-552 in combination with chemotherapeutic agents in lung cancer models. METHODS AND RESULTS: We combined of CIGB-552 and the antineoplastic agent Cisplatin (CDDP) in concomitant and pre-treatment scenary in a dose matrix approach. This study was performed in the non-small cell lung cancer cell lines NCI-H460, A549 and in a mouse model of TC-1 lung cancer. Our results demonstrate a clear synergic effect between 37.5 μM of CIGB-552 and 5 μM of CDDP under concomitant scheme, on proliferation inhibition, cell cycle arrest, apoptosis induction and oxidative stress response. The effect of CIGB-552 (1 mg/kg) and CDDP (0.4 mg/kg) administrated as a combined therapy was demonstrated in vivo in a TC-1 mouse model where the combination achieved an effective antitumor response, without any deterioration signs or side effects. CONCLUSIONS: These findings demonstrate the efficacy of the concomitant combination of both drugs in preclinical studies and support the use of this therapy in clinical trials. This study is the first evidence of synergistic effect of the combination of  the antitumoral peptide CIGB-552 and CDDP.